Antibody Archives | Be Korea-savvy

Home / Posts tagged Antibody

Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron

WALTHAM, Mass., Jan. 12 (Korea Bizwire) — Adagio Therapeutics, Inc., (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today summarized recent findings reported in three separate publications that show ADG20, its lead monoclonal antibody (mAb), has neutralization activity against the Omicron [...]

Junshi Biosciences Announces Acceptance by NMPA of Investigational New Drug Application for the Subcutaneous Injection of Anti-BLyS Monoclonal Antibody

SHANGHAI, China, Aug. 27 (Korea Bizwire) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted an investigational new drug application for UBP1213sc, its subcutaneous injection of recombinant humanized anti-BLyS [...]

Junshi Biosciences Announces Dosing of First Patient in Phase I Study of Anti-TROP2 Antibody -TUB196 Conjugate

SHANGHAI, China, Dec. 1 (Korea Bizwire) — Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that the Phase I clinical study (NCT04601285) of a recombinant humanized anti-TROP2 monoclonal antibody – Tub196 conjugate (JS108), has completed the dosing of the [...]

Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006

SHANGHAI, China, Dec. 1 (Korea Bizwire) — Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that the China National Medical Products Administration (NMPA) has recently accepted its Investigational New Drug (IND) application for JS006, a humanized monoclonal antibody against [...]

Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016 in China

SHANGHAI, China, July 12 (Korea Bizwire) — Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today the completion of study subjects enrollment in Phase I trial of SARS-CoV-2 neutralizing monoclonal antibody injection (Product Code: JS016), developed jointly with Institute of Microbiology, Chinese Academy [...]

S. Korea Aiming to Release Antibody Treatment Drug for COVID-19 in 2021

SEOUL, April 14 (Korea Bizwire) — South Korea seeks to carry out clinical tests on antibody-based treatment for the novel coronavirus within the year, with the aim of releasing a drug in 2021, a senior official said Tuesday. The country is mapping out a governmentwide support system to find a treatment method and vaccine to [...]

CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody

SAN DIEGO, Mar. 22 (Korea Bizwire) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced today a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed [...]

New Antibody Production Technology Reduces Dependence on Lab Animals

SEOUL, Aug. 24 (Korea Bizwire) – Antibodies play an essential role in the viral diagnosis of crops in Korea. The antibodies used are typically derived from blood samples of laboratory animals, such as rabbits and mice infected with a specific virus, once they are naturally produced by the animals’ immune systems. This poses various setbacks. [...]